Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...

Emergent BioSolutions (EBS) has secured a $51.9M contract modification award to deliver CNJ-016 to the Administration for Strategic Preparedness and Response (A ...

Investing.com -- Emergent BioSolutions Inc (NYSE: EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication ...

Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on Wednesday after the company announced the closing of a $100 million asset-backed revolving loan facility. The Details: The new ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

What happened. Shares of Emergent BioSolutions (EBS 1.45%) were sinking 12.8% lower as of 10:53 a.m. ET on Friday. The decline came after J.P. Morgan analyst Jessica Fye downgraded the stock from ...

Emergent BioSolutions faces declining revenues, increasing competition, and limited growth potential, leading to a sell rating due to poor risk-reward profile. NARCAN, their main revenue generator ...

Shares of drug manufacturer Emergent BioSolutions (EBS 0.16%) are down 75% in the past 12 months. Investors have been turning to safer investments amid the bear market and ditching the risky ...

BALTIMORE-- An additional 135 million doses of the coronavirus vaccine produced by Baltimore-based Emergent BioSolutions were rejected over quality control concerns, bringing the total number of ...